Anh Nguyen, Justin Chang, Timothy Allison-Aipa, Paul Albini
{"title":"A Comparison of Monotherapy and Combination Therapy With Antipsychotic Medications for Intensive Care Unit Delirium: A Retrospective Cohort Study.","authors":"Anh Nguyen, Justin Chang, Timothy Allison-Aipa, Paul Albini","doi":"10.1177/10600280251322199","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antipsychotic medications continue to be frequently prescribed by clinicians in the intensive care unit (ICU) for delirium, despite inconclusive data.</p><p><strong>Objective: </strong>To determine if using a combination of antipsychotics reduces the time patients spend in delirium compared with monotherapy.</p><p><strong>Methods: </strong>This was a single-center, retrospective, cohort medical record review of patients who scored positive on Confusion Assessment Method for the ICU (CAM-ICU) and received antipsychotic therapy. Patients were excluded if they received any antipsychotics prior to hospital admission or had a Richmond Agitation-Sedation Scale (RASS) scores of -4 or -5 at the time of CAM-ICU assessment. The primary outcome was duration of delirium. The secondary outcomes included ICU length of stay (LOS), hospital LOS, overall mortality, occurrence of adverse events (AEs), and whether antipsychotics were continued at hospital discharge.</p><p><strong>Results: </strong>A total of 84 patients were included, of these 45 and 39 received monotherapy and combination therapy, respectively. Median Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were significantly higher in the monotherapy group (18 vs 13, <i>P</i> = 0.006). Median duration of delirium was not significantly different between the monotherapy and combination therapy groups (8 vs 8 days, <i>P</i> = 0.932). Median ICU and hospital LOS, and occurrence of AEs were not significantly different. A significant difference in mortality was found between monotherapy and combination therapy (31% vs 10%, <i>P</i> = 0.02). Antipsychotics were continued at hospital discharge in 64% of the monotherapy and in 44% of the combination therapy group.</p><p><strong>Conclusion and relevance: </strong>In patients with ICU delirium, there was no difference in duration of delirium among patients receiving monotherapy compared with combination therapy with antipsychotics, though they may be sicker and have a higher mortality. Patients commonly remain on antipsychotics at hospital discharge, the implications of which warrant further study.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280251322199"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280251322199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Antipsychotic medications continue to be frequently prescribed by clinicians in the intensive care unit (ICU) for delirium, despite inconclusive data.
Objective: To determine if using a combination of antipsychotics reduces the time patients spend in delirium compared with monotherapy.
Methods: This was a single-center, retrospective, cohort medical record review of patients who scored positive on Confusion Assessment Method for the ICU (CAM-ICU) and received antipsychotic therapy. Patients were excluded if they received any antipsychotics prior to hospital admission or had a Richmond Agitation-Sedation Scale (RASS) scores of -4 or -5 at the time of CAM-ICU assessment. The primary outcome was duration of delirium. The secondary outcomes included ICU length of stay (LOS), hospital LOS, overall mortality, occurrence of adverse events (AEs), and whether antipsychotics were continued at hospital discharge.
Results: A total of 84 patients were included, of these 45 and 39 received monotherapy and combination therapy, respectively. Median Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were significantly higher in the monotherapy group (18 vs 13, P = 0.006). Median duration of delirium was not significantly different between the monotherapy and combination therapy groups (8 vs 8 days, P = 0.932). Median ICU and hospital LOS, and occurrence of AEs were not significantly different. A significant difference in mortality was found between monotherapy and combination therapy (31% vs 10%, P = 0.02). Antipsychotics were continued at hospital discharge in 64% of the monotherapy and in 44% of the combination therapy group.
Conclusion and relevance: In patients with ICU delirium, there was no difference in duration of delirium among patients receiving monotherapy compared with combination therapy with antipsychotics, though they may be sicker and have a higher mortality. Patients commonly remain on antipsychotics at hospital discharge, the implications of which warrant further study.
背景:尽管没有确凿的数据,但重症监护病房(ICU)的临床医生仍然经常开具抗精神病药物治疗谵妄。目的:确定与单一治疗相比,联合使用抗精神病药物是否能减少患者谵妄的时间。方法:这是一项单中心、回顾性、队列的医疗记录回顾,纳入了在ICU (CAM-ICU)混淆评估法(Confusion Assessment Method)中得分为阳性并接受抗精神病药物治疗的患者。如果患者在入院前接受过任何抗精神病药物或在CAM-ICU评估时里士满激动镇静量表(RASS)得分为-4或-5,则排除。主要观察指标为谵妄持续时间。次要结局包括ICU住院时间(LOS)、医院LOS、总死亡率、不良事件发生(ae)以及出院时是否继续使用抗精神病药物。结果:共纳入84例患者,其中单药治疗45例,联合治疗39例。单药组中位急性生理和慢性健康评估II (APACHE II)评分显著高于单药组(18 vs 13, P = 0.006)。谵妄持续时间中位数在单药组和联合治疗组之间无显著差异(8天vs 8天,P = 0.932)。ICU与医院的LOS中位数、ae的发生无显著差异。单药治疗和联合治疗的死亡率有显著差异(31% vs 10%, P = 0.02)。在单一治疗组和联合治疗组中,分别有64%和44%的患者在出院时继续服用抗精神病药物。结论及相关性:在ICU谵妄患者中,接受单一治疗与抗精神病药物联合治疗的患者谵妄持续时间没有差异,尽管他们可能病情更重,死亡率更高。患者通常在出院时继续服用抗精神病药物,其含义值得进一步研究。
期刊介绍:
Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days